Health Sciences Research Center, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11432, Saudi Arabia.
Department of Applied Biotechnology, Faculty of Chemistry, Warsaw University of Technology, 00-661 Warsaw, Poland.
Int J Mol Sci. 2024 Oct 8;25(19):10818. doi: 10.3390/ijms251910818.
Suppressor of cytokine signaling 2 (SOCS2), an E3 ubiquitin ligase, regulates the JAK/STAT signaling pathway, essential for cytokine signaling and immune responses. Its dysregulation contributes to cardiovascular diseases (CVDs) by promoting abnormal cell growth, inflammation, and resistance to cell death. This study aimed to elucidate the molecular mechanisms underlying the interactions between -derived proteins and peptides and SOCS2, with a focus on identifying potential therapeutic candidates for CVDs. Utilizing a multifaceted approach, advanced computational methodologies, including 3D structure modeling, protein-protein docking, 100 ns molecular dynamics (MD) simulations, and MM/PBSA calculations, were employed to assess the binding affinities and functional implications of -derived proteins on SOCS2 activity. The findings revealed that certain proteins, such as Lumbricin, Chemoattractive glycoprotein ES20, and Lumbrokinase-7T1, exhibited similar activities to standard antagonists in modulating SOCS2 activity. Furthermore, MM/PBSA calculations were employed to assess the binding free energies of these proteins with SOCS2. Specifically, Lumbricin exhibited an average ΔG of -59.25 kcal/mol, Chemoattractive glycoprotein ES20 showed -55.02 kcal/mol, and Lumbrokinase-7T1 displayed -69.28 kcal/mol. These values suggest strong binding affinities between these proteins and SOCS2, reinforcing their potential therapeutic efficacy in cardiovascular diseases. Further in vitro and animal studies are recommended to validate these findings and explore broader applications of -derived proteins.
细胞因子信号转导抑制因子 2(SOCS2)是一种 E3 泛素连接酶,调节 JAK/STAT 信号通路,对于细胞因子信号和免疫反应至关重要。其失调通过促进异常细胞生长、炎症和抵抗细胞死亡,导致心血管疾病(CVDs)。本研究旨在阐明 - 衍生蛋白和肽与 SOCS2 之间相互作用的分子机制,重点是确定 CVDs 的潜在治疗候选物。利用多方面的方法,包括 3D 结构建模、蛋白质-蛋白质对接、100ns 分子动力学(MD)模拟和 MM/PBSA 计算等先进的计算方法,评估了 - 衍生蛋白对 SOCS2 活性的结合亲和力和功能影响。研究结果表明,某些蛋白质,如蚯蚓蛋白、趋化吸引糖蛋白 ES20 和蚓激酶-7T1,在调节 SOCS2 活性方面表现出与标准拮抗剂相似的活性。此外,还采用 MM/PBSA 计算评估了这些蛋白质与 SOCS2 的结合自由能。具体来说,蚯蚓蛋白的平均 ΔG 为-59.25kcal/mol,趋化吸引糖蛋白 ES20 为-55.02kcal/mol,蚓激酶-7T1 为-69.28kcal/mol。这些值表明这些蛋白质与 SOCS2 之间具有很强的结合亲和力,这进一步证实了它们在心血管疾病中的潜在治疗效果。建议进行进一步的体外和动物研究来验证这些发现,并探索 - 衍生蛋白的更广泛应用。